Core Viewpoint - The article emphasizes the importance of improving the quality of life for patients with uremia through innovative treatment options and social responsibility initiatives, particularly highlighting the role of Jianfan Group in this endeavor [3][14]. Group 1: Medical Innovations - Over 3 million patients globally rely on dialysis, facing challenges in self-management and treatment delays, which affect their life expectancy [1] - Jianfan Group developed the HA130 blood perfusion device in 2004, which effectively removes medium and large molecular toxins that traditional dialysis cannot, filling a significant gap in treatment options [5][6] - The company has published over 3,000 clinical papers, with more than 300 included in international journals, establishing a strong evidence base for its products [6] Group 2: Clinical Application and Standardization - Jianfan has conducted extensive clinical trials, leading to the inclusion of its blood perfusion technology in clinical standard operating procedures and expert consensus guidelines [6][7] - The combination of dialysis and perfusion has been recognized as a standard treatment option, supported by a robust training and operational guideline framework [7] Group 3: Policy and Economic Impact - Recent healthcare reforms in China have made blood purification treatments more accessible and affordable for patients, with new guidelines for dialysis perfusion services introduced by the National Healthcare Security Administration [8] - Jianfan has responded to these reforms by reducing the prices of its perfusion devices while maintaining quality, thus enhancing patient access to innovative treatments [8] Group 4: Global Expansion and Market Position - Jianfan's blood perfusion technology has gained international recognition, with products entering over 8,000 hospitals worldwide and holding a market share of over 70% in the blood perfusion sector [10] - The company has obtained CE certification for multiple products, facilitating its entry into global markets and showcasing the success of Chinese innovation in high-end medical devices [10][11] Group 5: Social Responsibility and Community Engagement - Jianfan has established a dual system for corporate social responsibility, focusing on healthcare initiatives and community support, including the establishment of "Uremia Care Day" to raise awareness [12][14] - The company aims to unite government, medical institutions, and social organizations to protect the dignity of patients, exemplified by success stories of patients regaining mobility through their treatments [12][14]